Table 3.

Comparison between conventional echo, tissue Doppler parameters, and peak systolic strain in the main three longitudinal views of LV in controls and patients group before starting doxorubicin treatment.

	Control (n-30)	Patient group (n-25)	t-test	P value
FS %	35.78 ± 5.16	40 ± 4.87	2	0.05*
E (m/sec)	0.87 ± 0.11	0.77 ± 0.24	2.1	0.04*
A (m/sec)	0.52 ± 0.13	0.73 ± 0.13	3.3	0.005*
E/A	1.51 ± 0.4	1.60 ± 0.42	1.1	0.09
s (m/sec)	0.07 ± 0.02	0.06 ± 0.014	0.9	0.15
IVCT (ms)	83.1 ± 4.9	83.6 ± 4.2	1.8	0.08
e′ (m/sec)	0.12 ± 0.03	0.127 ± 0.011	0.5	0.52
a′ (m/sec)	0.07 ± 0.02	0.072 ± 0.020	0.8	0.25
e′/a′	1.88 ± 0.49	1.9 ± 0.4	0.75	0.53
IVRT (ms)	66.2 ± 3.6	67.1 ± 3.3	1.99	0.057
ALX	−22.2 ± 5.8%	−21.1 ± 5.3%	0.53	0.59
A4C	−21±2.4%	−18.9 ± 4.5%	1.86	0.07
A2C	−21±3.4%	−16.9 ± 7.3%	2.3	<0.03*
G	−21.5 ± 2.2%	−18.7 ± 4.5%	2.7	<0.01*

FS: fractional shortening, E: peak early filling velocity, A: Peak atrial phase filling velocity, s′: tissue Doppler peak mitral annulus systolic velocity, e′: tissue Doppler mitral flow early-phase filling velocity, a′: tissue Doppler peak atrial phase filling velocity, IVCT: isometric contraction time, IVRTL: Isometric relaxation time, ALX: apical long axis, A4C: apical 4-chamber, A2C: apical 2-chamber, views, and G: global peak systolic strain.